Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 179 • 2019 ACR/ARP Annual Meeting
The Burden of Comorbidity in Patients with RA, PSA or SPA in a General Practice Registry
Sofia Pazmino ¹, Veerle Stouten ¹, Patrick Verschueren ², Pavlos Mamouris ¹, Rene Westhovens ³, Kurt De Vlam ², Delphine Bertrand ¹, Kristien Van der Elst ², Bert Vaes ¹ and Diederik De Cock¹, ¹KU Leuven, Leuven, Belgium, ²University Hospital Leuven, Leuven, Belgium, ³University Hospitals, Leuven, Belgium
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PSA) and spondyloarthritis (SPA) are the most common inflammatory rheumatic diseases, associated with a high burden of comorbidities and…
Abstract Number: 1205 • 2019 ACR/ARP Annual Meeting
Real-World Remission Outcomes in the First Year Following RA Diagnosis Vary Considerably with the Disease Activity Index Used and a Sizable Proportion Have Persistent Active Disease Across All Measures: Results from the Canadian Early Arthritis Cohort (CATCH)
Orit Schieir¹, Susan J. Bartlett ², Marie-France Valois ³, Louis Bessette ⁴, Gilles Boire ⁵, Glen Hazlewood ⁶, Carol Hitchon ⁷, Edward Keystone ⁸, Janet Pope ⁹, Carter Thorne ¹⁰, Diane Tin ¹¹, Vivian Bykerk ¹² and Canadian Early Arthritis Cohort (CATCH) Investigators ¹³, ¹University of Toronto, Montreal, Canada, ²McGill University, Montreal, QC, Canada, ³McGill University, Montreal, Canada, ⁴Laval University, Quebec City, QC, Canada, ⁵Sherbrooke University, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, Canada, ⁷University of Manitoba, Winnipeg, Canada, ⁸Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁹Western University, London, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, Canada, ¹²Hospital for Special Surgery, New York City, NY, ¹³Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Early RA diagnosis and initiation of DMARDs following a treat-to -target approach is recommended to optimize remission outcomes. Several RA disease activity indices are…
Abstract Number: 2395 • 2019 ACR/ARP Annual Meeting
DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment
Theodore Pincus¹, jaquelin Chua ², Joel Block ² and Isabel Castrejon ², ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, chicago, IL
Background/Purpose: A study of patients with RA at their first visit to an academic rheumatology site indicated an unexpected observation that 75% of patients had…
Abstract Number: 198 • 2019 ACR/ARP Annual Meeting
Assessing Care Quality in Rheumatology Services
Mark Yates¹, Sam Norton ¹, Alexander MacGregor ², Katie Bechman ³, Sanketh Rampes ³ and James Galloway ⁴, ¹Kings College London, London, ²University of East Anglia, Norwich, United Kingdom, ³King's College London, London, United Kingdom, ⁴Kings College London, London, United Kingdom
Background/Purpose: There is high-quality evidence that prompt diagnosis and treatment have beneficial impact on outcomes in RA. Current guidelines from both North America and Europe…
Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting
Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Maria Powell¹, Vivian Bykerk ², Orit Schieir ³, Marie-France Valois ⁴, Susan J. Bartlett ⁵, Louis Bessette ⁶, Gilles Boire ⁷, Carol Hitchon ⁸, Edward Keystone ⁹, Janet Pope ¹⁰, Carter Thorne ¹¹, Diane Tin ¹² and Glen Hazlewood ¹, ¹University of Calgary, Calgary, AB, Canada, ²Hospital for Special Surgery, New York City, NY, ³University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, ⁴McGill University, Montreal, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Laval University, Quebec City, QC, Canada, ⁷Sherbrooke University, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, Canada, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Western University, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Southlake Regional Health Centre, Newmarket, Canada
Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…
Abstract Number: 2818 • 2019 ACR/ARP Annual Meeting
Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis
Virginia Muir ¹, Cliff Rims ¹, Kevin Deane ², Jeffrey Carlin ³, Sylvia Posso ¹, Sunil Nagpal ⁴, Navin Rao ⁴, Frédéric Baribaud ⁵, George Vratsanos ⁶, William Robinson ⁷, Gary Firestein ⁸, V. Michael Holers ⁹, Peter Linsley ¹, Eddie James¹ and Jane Buckner ¹, ¹Benaroya Research Institute, Seattle, WA, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³Virginia Mason Medical Center, Seattle, WA, ⁴Janssen R&D, Spring House, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶JNJ, Raritan, NJ, ⁷Stanford University, Palo Alto, CA, ⁸University of California, San Diego, San Diego, ⁹University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver
Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated…
Abstract Number: 451 • 2019 ACR/ARP Annual Meeting
Persistent and Non-Articular Regional and Widespread Pain Are Common in Early Rheumatoid Arthritis, Impacting Remission Rates and Reflected in Patient Global Scores
Vivian P. Bykerk¹, Orit Schieir ², Marie-France Valois ³, Gilles Boire ⁴, Glen Hazlewood ⁵, Louis Bessette ⁶, Carol Hitchon ⁷, Diane Tin ⁸, Carter Thorne ⁹, Edward Keystone ¹⁰, Janet Pope ¹¹, Susan J. Bartlett ¹² and Canadian Early Arthritis Cohort (CATCH) Investigators ¹³, ¹Hospital for Special Surgery, New York, NY, ²University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, ³McGill University, Montreal, Canada, ⁴Sherbrooke University, Sherbrooke, QC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Laval University, Quebec City, QC, Canada, ⁷University of Manitoba, Winnipeg, Canada, ⁸Southlake Regional Health Centre, Newmarket, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹¹Western University, London, ON, Canada, ¹²McGill University, Montreal, QC, Canada, ¹³Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Persisting pain (NRS ≥4,) (PP) and non-articular pain (NAP), reduces quality of life for patients with RA. NAP is often attributed to fibromyalgia (FM),…
Abstract Number: 1406 • 2019 ACR/ARP Annual Meeting
Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial
Maxime Verhoeven¹, Janneke Tekstra ¹, Attila Pethö-Schramm ², Michelle Borm ³, Jacob van Laar ¹, Floris Lafeber ¹, Johannes Bijlsma ¹, Johannes Jacobs ¹ and Paco Welsing ¹, ¹UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ²Hoffmann-La Roche, Basel, Basel, Switzerland, ³Roche Nederland BV, Woerden, Netherlands
Background/Purpose: U-Act-Early was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission. Patients were assigned to…
Abstract Number: 2846 • 2019 ACR/ARP Annual Meeting
Outcomes over the First 5 Years of Follow up in a Very Early Rheumatoid Arthritis (RA) Cohort Recruited over 20 Years: Most of the Improvement Occurred Before the 2011 Implementation of Treat-to-Target (T2T)
Nathalie Carrier ¹, Sophie Roux ², Ariel Masetto ², Artur deBrum Fernandes ², Patrick Liang ², Meryem Maoui ³ and Gilles Boire², ¹CIUSSS de l'Estrie-CHUS, Sherbrooke, QC, Canada, ²Université de Sherbrooke, Sherbrooke, QC, Canada, ³Bristol-Myers Squibb Canada, St-Laurent, QC, Canada
Background/Purpose: To analyze the evolution over 20 years of disease activity, treatments and radiographic progression over the first 5 years of follow up of patients…
Abstract Number: 460 • 2019 ACR/ARP Annual Meeting
Fertility of Women with Rheumatoid Arthritis: Disease Activity Negatively Correlates with Serum AMH Levels
Camille Valdeyron¹, Martin SOUBRIER ², Bruno Pereira ¹, Arnaud Constantin ³, Jacques Morel ⁴, Philippe Gaudin ⁵, Bernard Combe ⁶ and Florence Brugnon ¹, ¹CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ²CHU Gabriel Montpied, Clermont Ferrand, Auvergne, France, ³CHU TOUOUSE, TOULOUSE, France, ⁴CHU MONTPELLIER, MONTPELLIER, France, ⁵Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, ⁶CHU Montpellier, Montpellier University, Montpellier, France
Background/Purpose: Patients with rheumatoid arthritis (RA) display a higher infertility prevalence compared with the general population. Disease-related inflammation and RA treatments are likely to be…
Abstract Number: 1413 • 2019 ACR/ARP Annual Meeting
Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Naonobu Sugiyama ³, Noriko Iikuni ⁴, Koshika Soma ⁵, Harry Shi ⁶, Eduardo Mysler ⁷, Robert J. Moots ⁸, Josef Smolen ⁹ and Roy Fleischmann ¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Greater improvements in efficacy outcomes have been reported with tofacitinib 5 mg BID ±…
Abstract Number: 2851 • 2019 ACR/ARP Annual Meeting
Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations
Nina Sundlisater¹, Anna-Birgitte Aga ², Ulf Sundin ³, Hilde Hammer ¹, Till Uhlig ⁴, Tore Kvien ⁴, Espen Haavardsholm ⁴ and Siri Lillegraven ⁵, ¹Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, ²Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, ³Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway. University of Oslo, Oslo, Norway, Oslo, Oslo, Norway, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway
Background/Purpose: Abrogation of inflammation is important to prevent irreversible joint damage and maximize health-related quality of life in early RA patients. The ACR/EULAR Boolean remission…
Abstract Number: 470 • 2019 ACR/ARP Annual Meeting
Obesity Is a Robust Predictor of Persistent High Fatigue at 1 Year in Women and Men with Early Rheumatoid Arthritis
Susan J. Bartlett¹, Orit Schieir ², Marie-France Valois ³, Janet Pope ⁴, Louis Bessette ⁵, Carol Hitchon ⁶, Carter Thorne ⁷, Diane Tin ⁸, Glen Hazlewood ⁹, Gilles Boire ¹⁰, Edward Keystone ¹¹, Vivian Bykerk ¹² and Canadian Early Arthritis Cohort (CATCH) Investigators ¹³, ¹McGill University, Montreal, QC, Canada, ²University of Toronto, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴Western University, London, ON, Canada, ⁵Laval University, Quebec City, QC, Canada, ⁶University of Manitoba, Winnipeg, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, Canada, ⁹University of Calgary, Calgary, Canada, ¹⁰Sherbrooke University, Sherbrooke, QC, Canada, ¹¹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹²Hospital for Special Surgery, New York City, NY, ¹³Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: While treat-to-target strategies can dramatically reduce inflammation in RA, persistently high levels of fatigue are present in many patients and represent an important unmet need.…
Abstract Number: 1859 • 2019 ACR/ARP Annual Meeting
Joint Tenderness and Ultrasound Inflammation in DMARD-naïve Early Rheumatoid Arthritis Patients
Nina Sundlisater¹, Anna-Birgitte Aga ², Hilde Hammer ¹, Till Uhlig ³, Tore Kvien ³, Espen Haavardsholm ³ and Siri Lillegraven ⁴, ¹Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, ²Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, ³Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway
Background/Purpose: A tender joint count is part of most disease activity scores and remission criteria in rheumatoid arthritis (RA). A recent study in established RA…
Abstract Number: 2870 • 2019 ACR/ARP Annual Meeting
Persistence of B Cell-rich Synovitis Following Conventional Synthetic Disease Modifying Anti-Rheumatic Drug Treatment in Early Rheumatoid Arthritis Is Associated with Radiographic Progression Independently of Clinical Response
Felice Rivellese¹, Gloria Lliso-Ribera ², Alessandra Nerviani ¹, Frances humby ³ and Costantino Pitzalis ¹, ¹Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ²Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, ³Queen Mary University of London, London, United Kingdom
Background/Purpose: Synovial B cell aggregates in patients with early Rheumatoid Arthritis (RA) have been associated with disease severity and radiographic progression. Here, we analysed the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].